胰腺肿瘤 z-bio 2025-07-21 2632

　　On July 15, Shanghai Proton Heavy Ion Hospital (Proton Heavy Ion Center of the Affiliated Cancer Hospital of Fudan University) held a cadre meeting, and the board of directors of Shanghai Shenkang Hospital Development Center and the Heavy Ion Hospital announced the decision to appoint and dismiss and appoint the cadres. The appointment and removal decision of the Shenkang Center Party Committee was announced at the meeting: Comrade Yu Xianjun was appointed as the Party Committee and Director of Shanghai Proton Heavy Ion Clinical Technology R&D Center (Shanghai Proton Heavy Ion Hospital), and Comrade Guo Xiaomao no longer serves as the Party Committee and Director of the R&D Center (Hospital) due to age reasons. The board of directors' appointment decision was also read out at the meeting, and agreed to appoint Comrade Yu Xianjun as the director of Shanghai Proton Chongyi Hospital, Comrade Guo Xiaomao as the director of the hospital's clinical technical committee, and Comrade Jiang Guoliang as the honorary director of the clinical technical committee.

　　Pancreatic tumor expert

　　Responsible for the Director of Shanghai Proton Heavy Ion Hospital

　　Public information shows that Yu Xianjun was born in 1971. He is chief physician, second-level professor, doctoral supervisor of the dual disciplines of surgery and oncology. He is currently the director of the Affiliated Cancer Hospital of Fudan University, director of the Shanghai Pancreatic Oncology Research Institute, director of the Fudan University Pancreatic Oncology Research Institute, and director of the Shanghai Key Laboratory of Precision Treatment of Pancreatic Oncology. Yu Xianjun has been engaged in surgical work for more than 20 years. He has conducted postdoctoral research and clinical training on pancreatic cancer at Baylor College of Medicine and MD Anderson Cancer Center in the United States. He is good at surgical treatment and comprehensive treatment of various pancreatic tumors, neuroendocrine tumors, and hepatobiliary tumors. He is an expert in the field of pancreatic cancer.

　　Professor Yu Xianjun

　　In 2010, he founded the Pancreatic Surgery Department of the Affiliated Cancer Hospital of Fudan University and served as the department director. The number of pancreatic malignant tumor surgeries in the team accounts for about 1/3 of the total pancreatic surgery in Shanghai, ranking first in Shanghai for eight consecutive years. It has been built into an international first-class and leading pancreatic oncology medical teaching and research center. In April 2025, Professor Yu Xianjun's team, together with Peking University Cancer Hospital, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, etc., took five years of research to draw the world's first multiomics panoramic map of non-functional pancreatic neuroendocrine tumors, and proposed a breakthrough in the molecular classification framework, prognosis model and new targeted-immunotherapy strategies for this "silenced tumor", providing an important basis for clinical accurate diagnosis and treatment.

　　At this cadre appointment and removal meeting, Yu Xianjun said that after taking over the baton of the president of the Chongyi Hospital, he felt a great responsibility and glorious mission. In the future, he will further consolidate the hospital's first-mover advantage in the particle field, form more "Chinese solutions", and better build a world-class particle diagnosis and treatment R&D center to benefit tumor patients.

　　After resigning as dean

　　Guo Xiaomao is the director of the hospital's clinical technical committee

　　Professor Guo Xiaomao, who stepped down as the director of Shanghai Proton Heavy Ion Hospital this time, was born in 1965. He is a famous oncology disease expert. He is good at radiation treatment of breast tumors and abdominal tumors, especially in-depth research on radiation treatment and comprehensive treatment of tumor diseases such as breast cancer and liver cancer.

　　Professor Guo Xiaomao

　　In 2015, Shanghai Proton Heavy Ion Hospital was officially opened, and Professor Guo Xiaomao served as the first dean. He also worked in the Affiliated Cancer Hospital of Fudan University for a long time. In April 2011, Professor Guo Xiaomao began to serve as the director of the Affiliated Cancer Hospital of Fudan University. In 2023, he served as the Party Secretary of the Court. During his tenure as president and party secretary, Guo Xiaomao and the hospital leadership team actively established the National Cancer Medical Center. In June this year, he no longer served as the Party Secretary of the Court due to his age.

　　After resigning as the director of Shanghai Proton Heavy Ion Hospital this time, Professor Guo Xiaomao will serve as the director of the Clinical Technical Committee of Shanghai Proton Heavy Ion Hospital.

　　Guo Xiaomao said that he was honored and cherished to be the first director of the Heavy Ion Hospital and to work with everyone to create a precedent for domestic particle treatment. In the future, he will continue to firmly grasp the bottom line of clinical quality and safety in his new position and wholeheartedly contribute to the high-quality development of the hospital.

　　According to the official website information, Shanghai Proton Heavy Ion Hospital and Fudan University Affiliated Proton Heavy Ion Hospital are a tumor hospital integrating medical care, scientific research and teaching. They are also the first medical institution in China that has both proton and heavy ion radiation therapy technologies.

　　The hospital is located in Zhangjiang Science City, Pudong New District, Shanghai. It is built by the Shanghai Shenkang Hospital Development Center. It carries out actual clinical operations through high integration and resource sharing with the Affiliated Cancer Hospital of Fudan University. In May this year, Shanghai Proton Heavy Ion Hospital launched the second phase of the project. After the project is completed, the hospital is expected to become the world's largest particle clinical treatment center.